133242-63-4

Upstream product

• 4362-40-7 5-chloromethyl-2,2-dimethyl-1,3-dioxolane 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 23788-74-1 (R)-2,2-dimethyl-1,3-dioxolane-4-ylmethyl p-toluenesulfonate 
• 23737-51-1 solketal tosylate 

Downstream Products

• 133242-64-5 (2,2-dimethyl-1,3-dioxolan4-yl)methyl 3-[4-(2,3-epoxypropoxy)-phenyl]propionate 
• 133242-29-2 3-[4-((S)-2-Hydroxy-3-{2-[(morpholine-4-carbonyl)-amino]-ethylamino}-propoxy)-phenyl]-propionic acid (R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 133242-64-5 3-[4-((S)-1-Oxiranylmethoxy)-phenyl]-propionic acid (R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 133242-62-3 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]propionate 
• 144256-19-9 3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 133242-34-9 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(1,1-dimethyl-2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]-propionate 
• 144256-23-5 3-{4-[3-(1,1-Dimethyl-2-ureido-ethylamino)-2-hydroxy-propoxy]-phenyl}-propionic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 

Relevant academic research and scientific papers

Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.

Novel esters of phenylalkanoic acid

The esters of phenylalkanoic acid of the formula: STR1 wherein R 1 is 4-10 membered, saturated or unsaturated, mono- or bi-cyclic hetero ring containing as hetero atoms:(i) one or two nitrogen,(ii) two or three of nitrogen and sulfur in total, or(iii) one or two sulfur;R 2 is hydrogen; orR 1 and R 2, taken together with a nitrogen to which they are attached, form 4-7 membered, saturated or unsaturated, mono-cyclic hetero ring containing as hetero atoms:(i) one or two nitrogen, or(ii) two or three of nitrogen and oxygen in total,the aforementioned hetero rings, represented by R 1 or formed by R 1 and R 2, taken together with a nitrogen to which they are attached, may be substituted by one substituent selected from C1-4 alkyl and C2-5 acyl;R 3 each, independently, is hydrogen or C1-4 alkyl;R 4 is hydrogen, halogen, trihalomethyl, C1-4 alkyl, C1-4 alkoxy, C2-5 acyl, cyano, nitro or nitroxy;R 5 each, independently, is hydrogen, C1-4 alkyl or phenyl; or the two R 5 ''s, taken together with a carbon to which they are attached, form cyclopentane or cyclohexane;and the pharmaceutically acceptable acid addition salts thereof, have β 1 -adrenergic receptor blocking activity, and therefore, are useful for the prevention of and/or in the treatment of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia, etc.